Cat. No.: HY-U00248

Copy Link Print Information

LMP744

(Synonyms: MJ-III65; NSC706744)

Avis client

Based on 1 Customer Validation

LMP744 (MJ-III65) is a DNA intercalator and Topoisomerase I (Top1) inhibitor with antitumor activity.

Nos produits utilisent uniquement pour la recherche. Nous ne vendons pas aux patients.

Pureté: 98.33%
CAS No.: 308246-52-8
Formule: C₂₄H₂₄N₂O₇
Masse moléculaire:452.46

Stockage:

Powder -20°C, 3 years , 4°C, 2 years ; In solvent -80°C, 6 months , -20°C, 1 month

LMP744 Chemical Structure

CAS No.: 308246-52-8

Size

Prix

Stock

Quantité

Amount: USD 0.00

* Veuillez sélectionner la quantité avant d'ajouter des articles.

Top Publications Citing

Use of MCE Products

Fluorescent Dye

Strong Fluorescence Signal / Multi-Disciplinary Applications / High Fluorescence Specificity

Activité biologique
- Description
- IC₅₀ & Target
- Cellular Effect
- In Vitro
- In Vivo
Chemical Information
Solvant et solubilité
- In Vitro
Pureté et documentation
Références
Help & FAQs
Classifications
Bioz

Activité biologique

Description

LMP744 (MJ-III65) is a DNA intercalator and Topoisomerase I (Top1) inhibitor with antitumor activity^[1].

IC₅₀ & Target^[1]

Top1

Voir tous les produits spécifiques à Isoform Topoisomerase :

Cellular Effect

Cell Line	Type	Value	Description	References
DU-145	GI₅₀	<0.01 μM Compound: 5, MJ-III-65	Antiproliferative activity against human DU145 cells by SRB assay Antiproliferative activity against human DU145 cells by SRB assay	[PMID: 21710981]
DU-145	GI₅₀	<0.01 μM Compound: 5, MJ-III-65	Growth inhibition of human DU145 cells after 48 hrs by SRB assay Growth inhibition of human DU145 cells after 48 hrs by SRB assay	[PMID: 24800942]
DU-145	GI₅₀	<0.01 μM Compound: 4	Cytotoxicity against human DU145 cells Cytotoxicity against human DU145 cells	[PMID: 20630766]
DU-145	GI₅₀	<0.01 μM Compound: 6	Cytotoxicity against human DU145 cells Cytotoxicity against human DU145 cells	[PMID: 19783447]
DU-145	GI₅₀	>0.01 μM Compound: 5	Antiproliferative activity against human DU145 cells Antiproliferative activity against human DU145 cells	[PMID: 18630891]
DU-145	GI₅₀	0.02 μM Compound: 6; LMP744; MJ-III-65	Cytotoxicity against human DU145 cells by MTT assay Cytotoxicity against human DU145 cells by MTT assay	[PMID: 26906474]
DU-145	GI₅₀	0.02 μM Compound: 18c	Antiproliferative activity was determined for 50% growth inhibition against human Prostate DU-145 cell line Antiproliferative activity was determined for 50% growth inhibition against human Prostate DU-145 cell line	[PMID: 11020283]
HCT-116	GI₅₀	0.1 μM Compound: 5, MJ-III-65	Antiproliferative activity against human HCT116 cells by SRB assay Antiproliferative activity against human HCT116 cells by SRB assay	[PMID: 21710981]
HCT-116	GI₅₀	0.1 μM Compound: 5, MJ-III-65	Growth inhibition of human HCT116 cells after 48 hrs by SRB assay Growth inhibition of human HCT116 cells after 48 hrs by SRB assay	[PMID: 24800942]
HCT-116	GI₅₀	0.1 μM Compound: 4	Cytotoxicity against human HCT116 cells Cytotoxicity against human HCT116 cells	[PMID: 20630766]
HCT-116	GI₅₀	0.1 μM Compound: 5	Antiproliferative activity against human HCT116 cells Antiproliferative activity against human HCT116 cells	[PMID: 18630891]
HCT-116	GI₅₀	0.1 μM Compound: 6	Cytotoxicity against human HCT116 cells Cytotoxicity against human HCT116 cells	[PMID: 19783447]
HCT-116	GI₅₀	0.15 μM Compound: 6; LMP744; MJ-III-65	Cytotoxicity against human HCT116 cells by MTT assay Cytotoxicity against human HCT116 cells by MTT assay	[PMID: 26906474]
HCT-116	GI₅₀	0.15 μM Compound: 18c	Antiproliferative activity was determined for 50% growth inhibition against human colon HCT116 cell line Antiproliferative activity was determined for 50% growth inhibition against human colon HCT116 cell line	[PMID: 11020283]
HOP-62	GI₅₀	0.01 μM Compound: 6; LMP744; MJ-III-65	Cytotoxicity against human HOP62 cells by MTT assay Cytotoxicity against human HOP62 cells by MTT assay	[PMID: 26906474]
HOP-62	GI₅₀	0.01 μM Compound: 18c	Antiproliferative activity was determined for 50% growth inhibition against human lung HOP-62 cell line Antiproliferative activity was determined for 50% growth inhibition against human lung HOP-62 cell line	[PMID: 11020283]
HOP-62	GI₅₀	0.02 μM Compound: 19; MJIII-65; NSC 706744; LMP744	Cytotoxicity against human HOP62 cells after 48 hrs by SRB assay Cytotoxicity against human HOP62 cells after 48 hrs by SRB assay	[PMID: 28418653]
HOP-62	GI₅₀	0.02 μM Compound: 5, MJ-III-65	Antiproliferative activity against human HOP62 cells by SRB assay Antiproliferative activity against human HOP62 cells by SRB assay	[PMID: 21710981]
HOP-62	GI₅₀	0.02 μM Compound: 5, MJ-III-65	Growth inhibition of human HOP62 cells after 48 hrs by SRB assay Growth inhibition of human HOP62 cells after 48 hrs by SRB assay	[PMID: 24800942]
HOP-62	GI₅₀	0.02 μM Compound: 4	Cytotoxicity against human HOP62 cells Cytotoxicity against human HOP62 cells	[PMID: 20630766]
HOP-62	GI₅₀	0.02 μM Compound: 5	Antiproliferative activity against human HOP62 cells Antiproliferative activity against human HOP62 cells	[PMID: 18630891]
HOP-62	GI₅₀	0.02 μM Compound: 6	Cytotoxicity against human HOP62 cells Cytotoxicity against human HOP62 cells	[PMID: 19783447]
MCF7	GI₅₀	<0.01 μM Compound: 19; MJIII-65; NSC 706744; LMP744	Cytotoxicity against human MCF7 cells after 48 hrs by SRB assay Cytotoxicity against human MCF7 cells after 48 hrs by SRB assay	[PMID: 28418653]
MCF7	GI₅₀	<0.01 μM Compound: 5, MJ-III-65	Antiproliferative activity against human MCF7 cells by SRB assay Antiproliferative activity against human MCF7 cells by SRB assay	[PMID: 21710981]
MCF7	GI₅₀	<0.01 μM Compound: 5, MJ-III-65	Growth inhibition of human MCF7 cells after 48 hrs by SRB assay Growth inhibition of human MCF7 cells after 48 hrs by SRB assay	[PMID: 24800942]
MCF7	GI₅₀	<0.01 μM Compound: 4	Cytotoxicity against human MCF7 cells Cytotoxicity against human MCF7 cells	[PMID: 20630766]
MDA-MB-435	GI₅₀	0.68 μM Compound: 18c	Antiproliferative activity was determined for 50% growth inhibition against human breast MDA-MB-435 cell line Antiproliferative activity was determined for 50% growth inhibition against human breast MDA-MB-435 cell line	[PMID: 11020283]
MDA-MB-435	GI₅₀	0.79 μM Compound: 5	Antiproliferative activity against human MDA-MB-435 cells Antiproliferative activity against human MDA-MB-435 cells	[PMID: 18630891]
MDA-MB-435	GI₅₀	0.79 μM Compound: 6	Cytotoxicity against human MDA-MB-435 cells Cytotoxicity against human MDA-MB-435 cells	[PMID: 19783447]
OVCAR-3	GI₅₀	0.5 μM Compound: 19; MJIII-65; NSC 706744; LMP744	Cytotoxicity against human OVCAR3 cells after 48 hrs by SRB assay Cytotoxicity against human OVCAR3 cells after 48 hrs by SRB assay	[PMID: 28418653]
OVCAR-3	GI₅₀	0.5 μM Compound: 5, MJ-III-65	Antiproliferative activity against human OVCAR3 cells by SRB assay Antiproliferative activity against human OVCAR3 cells by SRB assay	[PMID: 21710981]
OVCAR-3	GI₅₀	0.5 μM Compound: 5, MJ-III-65	Growth inhibition of human OVCAR3 cells after 48 hrs by SRB assay Growth inhibition of human OVCAR3 cells after 48 hrs by SRB assay	[PMID: 24800942]
OVCAR-3	GI₅₀	0.5 μM Compound: 4	Cytotoxicity against human OVCAR-3 cells Cytotoxicity against human OVCAR-3 cells	[PMID: 20630766]
OVCAR-3	GI₅₀	0.5 μM Compound: 5	Antiproliferative activity against human OVCAR-3 cells Antiproliferative activity against human OVCAR-3 cells	[PMID: 18630891]
OVCAR-3	GI₅₀	0.5 μM Compound: 6	Cytotoxicity against human OVCAR-3 cells Cytotoxicity against human OVCAR-3 cells	[PMID: 19783447]
OVCAR-3	GI₅₀	1.5 μM Compound: 6; LMP744; MJ-III-65	Cytotoxicity against human OVCAR3 cells by MTT assay Cytotoxicity against human OVCAR3 cells by MTT assay	[PMID: 26906474]
OVCAR-3	GI₅₀	1.5 μM Compound: 18c	Antiproliferative activity was determined for 50% growth inhibition against human ovarian OVCAR-3 cell line Antiproliferative activity was determined for 50% growth inhibition against human ovarian OVCAR-3 cell line	[PMID: 11020283]
SF-539	GI₅₀	0.04 μM Compound: 19; MJIII-65; NSC 706744; LMP744	Cytotoxicity against human SF539 cells after 48 hrs by SRB assay Cytotoxicity against human SF539 cells after 48 hrs by SRB assay	[PMID: 28418653]
SF-539	GI₅₀	0.04 μM Compound: 5, MJ-III-65	Antiproliferative activity against human SF539 cells by SRB assay Antiproliferative activity against human SF539 cells by SRB assay	[PMID: 21710981]
SF-539	GI₅₀	0.04 μM Compound: 5, MJ-III-65	Growth inhibition of human SF539 cells after 48 hrs by SRB assay Growth inhibition of human SF539 cells after 48 hrs by SRB assay	[PMID: 24800942]
SF-539	GI₅₀	0.04 μM Compound: 4	Cytotoxicity against human SF539 cells Cytotoxicity against human SF539 cells	[PMID: 20630766]
SF-539	GI₅₀	0.04 μM Compound: 5	Antiproliferative activity against human SF539 cells Antiproliferative activity against human SF539 cells	[PMID: 18630891]
SF-539	GI₅₀	0.04 μM Compound: 6	Cytotoxicity against human SF539 cells Cytotoxicity against human SF539 cells	[PMID: 19783447]
SF-539	GI₅₀	0.09 μM Compound: 6; LMP744; MJ-III-65	Cytotoxicity against human SF539 cells by MTT assay Cytotoxicity against human SF539 cells by MTT assay	[PMID: 26906474]
SF-539	GI₅₀	0.09 μM Compound: 18c	Antiproliferative activity was determined for 50% growth inhibition against human CNS SF-539 cell line Antiproliferative activity was determined for 50% growth inhibition against human CNS SF-539 cell line	[PMID: 11020283]
SN12C	GI₅₀	<0.01 μM Compound: 19; MJIII-65; NSC 706744; LMP744	Cytotoxicity against human SN12C cells after 48 hrs by SRB assay Cytotoxicity against human SN12C cells after 48 hrs by SRB assay	[PMID: 28418653]
SN12C	GI₅₀	<0.01 μM Compound: 5, MJ-III-65	Antiproliferative activity against human SN12C cells by SRB assay Antiproliferative activity against human SN12C cells by SRB assay	[PMID: 21710981]
SN12C	GI₅₀	<0.01 μM Compound: 5, MJ-III-65	Growth inhibition of human SN12C cells after 48 hrs by SRB assay Growth inhibition of human SN12C cells after 48 hrs by SRB assay	[PMID: 24800942]
SN12C	GI₅₀	<0.01 μM Compound: 4	Cytotoxicity against human SN12C cells Cytotoxicity against human SN12C cells	[PMID: 20630766]
SN12C	GI₅₀	<0.01 μM Compound: 6	Cytotoxicity against human SN12C cells Cytotoxicity against human SN12C cells	[PMID: 19783447]
SN12C	GI₅₀	>0.01 μM Compound: 5	Antiproliferative activity against human SN12C cells Antiproliferative activity against human SN12C cells	[PMID: 18630891]
SN12C	GI₅₀	0.01 μM Compound: 6; LMP744; MJ-III-65	Cytotoxicity against human SN12C cells by MTT assay Cytotoxicity against human SN12C cells by MTT assay	[PMID: 26906474]
SN12C	GI₅₀	0.01 μM Compound: 18c	Antiproliferative activity was determined for 50% growth inhibition against human renal SN12C cell line Antiproliferative activity was determined for 50% growth inhibition against human renal SN12C cell line	[PMID: 11020283]
UACC-62	GI₅₀	0.03 μM Compound: 19; MJIII-65; NSC 706744; LMP744	Cytotoxicity against human UACC62 cells after 48 hrs by SRB assay Cytotoxicity against human UACC62 cells after 48 hrs by SRB assay	[PMID: 28418653]
UACC-62	GI₅₀	0.03 μM Compound: 5, MJ-III-65	Antiproliferative activity against human UACC62 cells by SRB assay Antiproliferative activity against human UACC62 cells by SRB assay	[PMID: 21710981]
UACC-62	GI₅₀	0.03 μM Compound: 5, MJ-III-65	Growth inhibition of human UACC62 cells after 48 hrs by SRB assay Growth inhibition of human UACC62 cells after 48 hrs by SRB assay	[PMID: 24800942]
UACC-62	GI₅₀	0.03 μM Compound: 6; LMP744; MJ-III-65	Cytotoxicity against human UACC62 cells by MTT assay Cytotoxicity against human UACC62 cells by MTT assay	[PMID: 26906474]
UACC-62	GI₅₀	0.03 μM Compound: 18c	Antiproliferative activity was determined for 50% growth inhibition against human melanoma UACC-62 cell line Antiproliferative activity was determined for 50% growth inhibition against human melanoma UACC-62 cell line	[PMID: 11020283]
UACC-62	GI₅₀	0.03 μM Compound: 4	Cytotoxicity against human UACC62 cells Cytotoxicity against human UACC62 cells	[PMID: 20630766]
UACC-62	GI₅₀	0.03 μM Compound: 5	Antiproliferative activity against human UACC62 cells Antiproliferative activity against human UACC62 cells	[PMID: 18630891]
UACC-62	GI₅₀	0.03 μM Compound: 6	Cytotoxicity against human UACC62 cells Cytotoxicity against human UACC62 cells	[PMID: 19783447]

In Vitro

The GI₅₀ value of LMP744 (MJ-III-65) for NCI60 cells is 0.1 μM^[2].
LMP744 (0.1-5 μM, 3 days) induces dose-dependent accumulation of cells in the S and G₂ phases of the cell cycle^[2].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Cell Viability Assay^[2]

Cell Line:

P388 and P388 Top1-deficient murine leukemia cells
Concentration:

0.1-100 μM
Incubation Time:

3 days
Result:

Induced dose-dependent accumulation of cells in the S and G₂ phases of the cell cycle.

In Vivo

LMP744 (MJ-III65) (10-50 mg/kg) administered i.v. push once a week for 4 weeks in nude mice moderately actives against human A253 and FaDu tumor xenografts without significant toxicity^[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model:

Athymic nude mice (nu/nu, female, 20-25 g, 8-12 weeks old) transplanted with A253 and FaDu human head and neck xenografts^[1].
Dosage:

10, 25, or 50 mg/kg/week, 4 weeks
Administration:

I.V. push via tail vein
Result:

Moderately actived against human A253 and FaDu tumor xenografts without significant toxicity.

Chemical Information

CAS No. 308246-52-8
Appearance Solid
Masse moléculaire 452.46
Formule C₂₄H₂₄N₂O₇
Color Brown to dark brown
SMILES

OCCNCCCN1C2=C(C(C3=CC(OCO4)=C4C=C23)=O)C5=CC(OC)=C(OC)C=C5C1=O
Synonyms

MJ-III65; NSC706744
Livraison

Room temperature in continental US; may vary elsewhere.

Stockage

Powder	-20°C	3 years
	4°C	2 years
In solvent	-80°C	6 months
	-20°C	1 month

Solvant et solubilité

In Vitro:

DMSO : ≥ 4.17 mg/mL (9.22 mM; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)

* "≥" means soluble, but saturation unknown.

View the Complete Stock Solution Preparation Table

Preparing Stock Solutions

View the Complete Stock Solution Preparation Table

Concentration Solvent Mass

1 mg

5 mg

10 mg

Concentration

Solvent

Mass

1 mM

2.2101 mL

11.0507 mL

22.1014 mL

5 mM

0.4420 mL

2.2101 mL

4.4203 mL

10 mM

---

Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.

Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.

Calculateur de molarité

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Mass Mass

Concentration Concentration

Volume Volume

Molecular Weight Molecular Weight

Calculateur de dilution

Concentration _(start) × Volume _(start) = Concentration _(final) × Volume _(final)

Concentration _(start) Concentration _(start)

Volume _(start) Volume _(start)

Concentration _(final) Concentration _(final)

Volume _(final) Volume _(final)

Pureté et documentation

Select Batch:

Pureté: 99.98%

Assay: 99.98%

ee.: 99.98%

Fiche technique (273 KB)
SDS (252 KB)
- English - EN (252 KB)
- Français - FR (252 KB)
- Deutsch - DE (252 KB)
- Norwegian - NO (252 KB)
- Español - ES (252 KB)
- Swedish - SV (252 KB)
- Italian - IT (252 KB)
- Korean - KR (252 KB)
- Portuguese - PT (252 KB)
COA (2659 KB)
Elemental Analysis Report (2659 KB)
HNMR (2659 KB)
CNMR (2659 KB)
RP-HPLC (2659 KB)
NP-HPLC (2659 KB)
MS (2659 KB)
LCMS (2659 KB)
IR (2659 KB)
GC (2659 KB)
OR (2659 KB)
SDS-PAGE (2659 KB)
SEC-HPLC (2659 KB)
Other Report (2659 KB)
Instruction de manipulation (2659 KB)

Références

[1]. Antony S, et al. Cellular topoisomerase I inhibition and antiproliferative activity by MJ-III-65 (NSC 706744), an indenoisoquinoline topoisomerase I poison. Mol Pharmacol. 2005 Feb;67(2):523-30. [Content Brief]

[2]. Antony S, et al. Novel indenoisoquinolines NSC 725776 and NSC 724998 produce persistent topoisomerase I cleavage complexes and overcome multidrug resistance. Cancer Res. 2007 Nov 1;67(21):10397-405. [Content Brief]

Help & FAQs

How should lyophilized recombinant proteins be reconstituted and stored?

1. Before opening the cap, centrifuge the vial at 13000 rpm for 20-30 seconds. This step will ensure that any lyophilized powder that may have adhered to the cap or walls is collected at the bottom of the vial, minimizing the risk of product loss.

Complete Stock Solution Preparation Table

Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.

Optional Solvent	Concentration Solvent Mass	1 mg	5 mg	10 mg	25 mg
DMSO	1 mM	2.2101 mL	11.0507 mL	22.1014 mL	55.2535 mL
DMSO	5 mM	0.4420 mL	2.2101 mL	4.4203 mL	11.0507 mL

Keywords

Nom du produit:
Cat. No.:
Quantité:
MCE Japan Authorized Agent:

Nom du produit:
CAS No.:
Species:
Pureté:
Quantité:

LMP744

Anti-Lung Cancer Compound Library

Highly Selective Inhibitors Library

Bioactive Compound Library Max

Bioactive Compound Library

High-Throughput Bioactive Compound Library

Cell Cycle/DNA Damage Compound Library

Anti-Cancer Compound Library

Anti-Aging Compound Library

Voir tous les produits spécifiques à Isoform Topoisomerase

Activité biologique

Chemical Information

Solvant et solubilité

Pureté et documentation

Références

Help & FAQs

Complete Stock Solution Preparation Table

LMP744

Anti-Lung Cancer Compound Library

Highly Selective Inhibitors Library

Bioactive Compound Library Max

Bioactive Compound Library

High-Throughput Bioactive Compound Library

Cell Cycle/DNA Damage Compound Library

Anti-Cancer Compound Library

Anti-Aging Compound Library

Voir tous les produits spécifiques à Isoform Topoisomerase

Activité biologique

Chemical Information

Solvant et solubilité

Pureté et documentation

Références

Help & FAQs

Complete Stock Solution Preparation Table

LMP744 Related Classifications

HY-U00248 Related Classifications